NASDAQHealth CareMedical Instruments & SuppliesSnapshot 2026-07-23
Reading ANGO? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
ANGO represents a speculative growth investment. The company is currently loss-making and faces elevated risks, but it has shown some progress in sales growth, making it a name to watch in the healthcare sector.
The market appears to have priced in a justified valuation, with ANGO being considered cheap compared to its peers. However, there is a significant expectations gap, indicating that the market anticipates challenges ahead.
Fundamentals are likely to remain weak in the near term, as management has struggled to achieve key financial targets, such as positive free cash flow and maintaining gross margins. Recent earnings results have been erratic, contributing to a cautious outlook.
The thesis hinges on the performance of sector bellwethers like ISRG, MDLN, and BDX. If these companies continue to perform well, it could provide a tailwind for ANGO. Conversely, if they miss expectations, ANGO may face additional headwinds.
Over the next 1 to 3 years, ANGO's performance will largely depend on its ability to navigate sector dynamics and improve its financial metrics. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. This improvement is driven by AngioDynamics' latest earnings beat and an increased sales outlook for fiscal 2027, which supports growth objectives. There are no current threats impacting the thesis.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Meeting the sales target shows growth and good strategy execution.
Confirms:Net sales for FY 2026 reach between $313.5M and $315.5M.
Disproves:Net sales for FY 2026 fall below $313.5M, indicating weaker performance.
Why it matters: This would indicate a slowdown in the Med Tech segment, which is key for overall growth.
Confirms:Med Tech net sales growth below 15% year over year in Q3.
Disproves:Med Tech net sales growth remains at or above 15% year over year.
Why it matters: A drop below this level may show problems with cost management and pricing.
Confirms:Gross margin reported below 53.5% in Q3.
Disproves:Gross margin remains at or above 53.5% in Q3.
Why it matters: The lawsuit result could change AngioDynamics' market position. It may also lower investor trust.
Confirms:A favorable ruling or settlement in the lawsuit.
Disproves:A decision against AngioDynamics could hurt them. A long legal battle without a solution is also a risk.
Why it matters: Keeping gross margin is important for making money. It affects overall financial results.
Confirms:Gross margin for Q4 FY 2026 stays between 53.5% and 55.5%.
Disproves:Gross margin for Q4 FY 2026 falls below 53.5%, indicating margin pressure.
Why it matters: The earnings report will show if AngioDynamics can improve its loss-making status. Investors will focus on revenue and profit trends.
Confirms one read:Earnings report shows revenue growth above 10% year over year.
Confirms the other:Earnings report shows revenue decline or continued losses.
Why it matters: If the health care sector's revenue growth speeds up, it could benefit AngioDynamics. A stronger sector may improve investor sentiment.
Confirms:Sector revenue growth is speeding up again. It is now above 10% year over year.
Disproves:Sector revenue growth is slowing down. It is now below 10% year over year.
Why it matters: Positive free cash flow is important for AngioDynamics' finances. It shows they can make cash.
Confirms:Free cash flow for Q4 FY 2026 is now positive. This means better cash generation.
Disproves:Free cash flow is still negative for Q4 FY 2026. This shows cash generation problems continue.
Why it matters: New partnerships could enhance market position and drive future growth.
Confirms:New strategic partnerships were announced in Q3.
Disproves:No new strategic partnerships announced in Q3.
